Education
About Us
Working with TipRanks
Follow Us
ScandiDos AB (SE:SDOS)
:SDOS
Top Page
ScandiDos AB
(SDOS)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr1.00
▼(-13.04% Downside)
The score is held back primarily by weak financial performance: recurring losses and negative, worsening free cash flow despite stable revenue. Support comes from a low-debt balance sheet that reduces financial distress risk and moderately improving near-term technical momentum, but valuation remains challenged due to loss-making results.
ScandiDos AB (SDOS) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr67.84M
Dividend YieldN/A
Average Volume (3M)69.69K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)<0.01
Shares Outstanding57,011,086
10 Day Avg. Volume66,689
30 Day Avg. Volume69,692
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.28
Price to Sales (P/S)0.95
P/FCF Ratio-21.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ScandiDos AB Business Overview & Revenue Model
Company DescriptionScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; and Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation. The company was founded in 2005 and is headquartered in Uppsala, Sweden.
How the Company Makes Money
ScandiDos AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.49M | 60.43M | 60.43M | 61.55M | 57.68M | 59.99M |
| Gross Profit | 32.52M | 47.55M | 47.55M | 52.95M | 47.92M | 49.73M |
| EBITDA | 571.00K | -5.79M | -13.36M | -8.26M | -7.11M | -1.58M |
| Net Income | -1.38M | -14.65M | -14.65M | -9.12M | -7.34M | -1.40M |
Balance Sheet | ||||||
| Total Assets | 68.29M | 73.38M | 81.47M | 72.42M | 66.19M | 77.16M |
| Cash, Cash Equivalents and Short-Term Investments | 5.70M | 10.06M | 1.53M | 3.55M | 6.24M | 9.00M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00K |
| Total Liabilities | 25.09M | 28.40M | 37.19M | 30.77M | 28.99M | 31.98M |
| Stockholders Equity | 43.19M | 44.98M | 44.29M | 41.65M | 37.20M | 45.18M |
Cash Flow | ||||||
| Free Cash Flow | -1.72M | -2.71M | -1.46M | -16.31M | -2.31M | 4.08M |
| Operating Cash Flow | -1.10M | 230.00K | 1.49M | -11.90M | 2.39M | 8.64M |
| Investing Cash Flow | -1.72M | -2.94M | -2.94M | -4.37M | -4.77M | -4.63M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 12.33M | -83.00K | -1.66M |
ScandiDos AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:SDOS
ScandiDos AB
1.19
-0.40
-25.16%
DE:LS60
Clinical Laserthermia Systems AB Class B
0.79
0.52
195.11%
DE:2OK
SpectraCure AB
0.01
-0.09
-90.00%
DE:24C
C-Rad AB Class B
2.88
0.45
18.52%
DE:LUR
Luxbright AB
0.04
-0.03
-41.79%
DE:MN2
Mentice AB
1.33
-0.75
-35.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.